

**IMAGION BIOSYSTEMS LIMITED**

ASX: IBX

6 January 2026

**Cleansing Notice – Issue of Shares**

Imagion Biosystems (ASX: IBX) (**Company** or **Imagion**), a company dedicated to improving healthcare outcomes through the early detection of cancer utilising its proprietary MagSense® imaging technology, lodges the following cleansing notice for the new ordinary shares issued upon the vesting of performance rights issued to Executive Chairman, Mr. Robert Proulx. The Company issued 1,400,000 ordinary shares at a deemed issue price of 2.2 cents each, the market price of the Company's shares on the date of issue, as set out in the Appendix 2A released today.

**Section 708A Cleansing Notice**

The Company gives notice under Section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act) that:

- (a) it issued 1,400,000 fully paid ordinary shares (Shares) on 29 December 2025;
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act
- (d) as at the date of this notice the Company has complied with:
  - i. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - ii. sections 674 and 674A of the Corporations Act; and
- (e) as at the date of this notice, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed pursuant to section 708A(6)(e).

The Board of IBX believes it is prudent to highlight that as per prior ASX releases, the HER2+ Phase 2 CT IND submission is expected to be submitted with the FDA in the near term.

**Authorisation & Additional Information**

This announcement was authorised by the Board of Imagion Biosystems Limited.

— ENDS —

**Imagion Biosystems Limited**

ASX: IBX ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

<http://www.imagionbiosystems.com/> | [investor@imagionbio.com](mailto:investor@imagionbio.com)

**About Imagion Biosystems**

Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular imaging technology. Combining biotechnology and nanotechnology, the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. For more information, visit <https://imaginationbiosystems.com/investor-hub/>

**Executive Chairman Contact Details**

Bob Proulx

[investor@imaginationbio.com](mailto:investor@imaginationbio.com)

AU: +61 3 9692 7222

**Media Enquiries & Investor Relations:**

Erich Boileau, Boileau & Co.

[imaginationbio@boileau.co](mailto:imaginationbio@boileau.co)

US : +1 (616) 786-4461

**Imagion Biosystems Limited**

ASX: **IBX** ACN 616 305 027

Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000

<http://www.imaginationbiosystems.com/> | [investor@imaginationbio.com](mailto:investor@imaginationbio.com)

